NCT00195546View on ClinicalTrials.gov

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

PHASE3CompletedINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

January 31, 2006

Conditions
Menopause
Interventions
DRUG

DVS-233

Trial Locations (41)

2800

Tatabánya

3000

Leuven

4031

Debrecen

7500

Parow

9301

Bloemfontein

10000

Zagreb

23000

Zadar

28009

Madrid

58185

Linköping

70100

Kuopio

70110

Kuopio

70200

Ostrava

75002

Přerov

75005

Paris

75012

Paris

75185

Uppsala

77200

Olomuc

83114

Donetsk

90100

Oulu

91024

Évry

510401

Stockholm

CP06727

Del. Cuauhtemoc

CP11000

Lomas Virrteyes

5223 GV

's-Hertogenbosch

7555 PJ

Hengelo

6533 NV

Nijmegen

40-125

Katowice

60-535

Poznan

02-341

Warsaw

50-088

Wroclaw

020475

Bucharest

021659

Bucharest

050098

Bucharest

060251

Bucharest

0157

Centurion

01034

Kyiv

04112

Kyiv

PL23 1DT

Fowey

LE2 7LX

Leicester

W12 0HS

London

PL6 7TH

Plymouth

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00195546 - Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause | Biotech Hunter | Biotech Hunter